Erytech Pharma: Dense Newsflow During Next 12 Months
Edison | Jul 29, 2016 06:51AM ET
Erytech Pharma (PA:ERYP) lead indication, acute lymphocytic leukaemia (ALL), is being explored in a comprehensive programme for its Graspa technology, with acute myeloid leukemia (AML) and pancreatic cancer following next. Key clinical data are expected for all three indications during the next 12 months, with the hallmark event being expected approval of the marketing application for Graspa for relapsed/refractory ALL in Europe by end-2016/early 2017. Our valuation of Erytech remains largely unchanged at €322m.
Key catalysts to mid-2017
With Graspa already filed in Europe in relapsed/refractory ALL and a decision expected by end-2016, the focus is now on the US and new indications. A Phase Ib study in ALL in the US is ongoing with data expected in 2016. This could potentially allow rolling out development into front-line ALL globally. A Phase IIb trial in AML is more than 90% recruited, with primary results expected in mid-2017. A Phase II trial in pancreatic cancer is the first solid tumour indication and results should be released in Q416.
To read the entire report Please click on the pdf File Below
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.